共 53 条
Management of candidemia and invasive candidiasis
被引:5
作者:
Taieb, F.
[1
,2
]
Mechai, F.
[1
,2
]
Lefort, A.
[3
]
Lanternier, F.
[1
,2
]
Bougnoux, M. -E.
[6
]
Lortholary, O.
[1
,2
,4
,5
]
机构:
[1] Ctr Infectiol Necker Pasteur, Paris, France
[2] Univ Paris 05, Hop Necker Enfants Malad, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75743 Paris 15, France
[3] Univ Paris Diderot, Hop Beaujon, Serv Med Interne, F-92110 Clichy, France
[4] Ctr Natl Reference Mycol & Antifong, Inst Pasteur, F-75015 Paris, France
[5] CNRS, URA 3012, Paris, France
[6] Univ Paris 05, Hop Necker Enfants Malad, Serv Mycol & Parasitol, F-75015 Paris, France
来源:
REVUE DE MEDECINE INTERNE
|
2011年
/
32卷
/
03期
关键词:
Candida spp;
Invasive infection;
Treatment;
BLOOD-STREAM INFECTIONS;
INTENSIVE-CARE-UNIT;
HOSPITAL-ACQUIRED CANDIDEMIA;
IN-VITRO SUSCEPTIBILITIES;
LIPOSOMAL AMPHOTERICIN-B;
RISK-FACTORS;
FUNGAL-INFECTIONS;
RANDOMIZED-TRIAL;
CANCER-PATIENTS;
EPIDEMIOLOGY;
D O I:
10.1016/j.revmed.2010.08.019
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Candida species is the fourth most common cause of bloodstream infection and is the leading cause of invasive fungal infection among hospitalized patients. Acute disseminated candidiasis remains a life-threatening disease that now occurs mainly in intensive care units hospitalized patients. Delay in treatment of Candida bloodstream infections could be minimized by the development of more rapid and sensitive diagnostic techniques for the identification of Candida bloodstream infections. Current guidelines for the management of invasive candidiasis recommend fluconazole or an echinocandin as the primary therapeutic option. The optimal choice of the antifungal agent should depend on local epidemiology, prior antifungal therapy and patient's characteristics. (c) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:173 / 180
页数:8
相关论文